Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Afatinib, sold under the brand name Gilotrif among others, is a medication which is used to treat non-small cell lung carcinoma (NSCLC). It belongs to the tyrosine kinase inhibitor family of medications. It is taken by mouth.
Adverse effects, Mechanism of action & Clinical trials
Explore the main themes, entities and connections around Afatinib. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
egfr nsclc phase breast iii drug lung mutations epidermal growth factor receptor used drugs protein name gilotrif mouth cancer cancers
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Afatinib | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Afatinib | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Afatinib | ATC code | L01EB03 (WHO) | 1.00 | infobox |
| Afatinib | CAS Number | 850140-72-6 Y[Drugbank] | 1.00 | infobox |
| Afatinib | ChEBI | CHEBI:61390 Y | 1.00 | infobox |
| Afatinib | ChEMBL | ChEMBL1173655 Y | 1.00 | infobox |
| Afatinib | ChemSpider | 8360155 Y | 1.00 | infobox |
| Afatinib | CompTox Dashboard (EPA) | DTXSID20893451 | 1.00 | infobox |
| Afatinib | DrugBank | DB08916 Y | 1.00 | infobox |
| Afatinib | ECHA InfoCard | 100.239.035 | 1.00 | infobox |
| Afatinib | Elimination half-life | 37 hours | 1.00 | infobox |
| Afatinib | Excretion | Faeces (85%), urine (4%) | 1.00 | infobox |
| Afatinib | Formula | C24H25ClFN5O3 | 1.00 | infobox |
| Afatinib | IUPHAR/BPS | 5667 | 1.00 | infobox |
| Afatinib | KEGG | D09724 N | 1.00 | infobox |
| Afatinib | KEGG | as salt: D09733 N | 1.00 | infobox |
| Afatinib | Legal status | AU: S4 (Prescription only) | 1.00 | infobox |
| Afatinib | Legal status | CA: ℞-only | 1.00 | infobox |
| Afatinib | Legal status | UK: POM (Prescription only) | 1.00 | infobox |
| Afatinib | Legal status | US: ℞-only | 1.00 | infobox |
| Afatinib | Legal status | EU: Rx-only | 1.00 | infobox |
| Afatinib | License data | EU EMA: by INN | 1.00 | infobox |
| Afatinib | License data | US DailyMed: Afatinib | 1.00 | infobox |
| Afatinib | MedlinePlus | a613044 | 1.00 | infobox |
| Afatinib | Metabolism | CYP not involved | 1.00 | infobox |
| Afatinib | Molar mass | 485.94 g·mol−1 | 1.00 | infobox |
| Afatinib | Other names | BIBW 2992 | 1.00 | infobox |
| Afatinib | Pregnancy category | AU: C | 1.00 | infobox |
| Afatinib | Protein binding | 95% | 1.00 | infobox |
| Afatinib | PubChem CID | 10184653 | 1.00 | infobox |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.